Literature DB >> 13006812

[The use of radioactive dyes in the diagnosis of neoplasms].

H CRAMER, H W PABST, A TREIBS.   

Abstract

Entities:  

Keywords:  NEOPLASMS/diagnosis; STAINS AND STAINING

Mesh:

Substances:

Year:  1952        PMID: 13006812

Source DB:  PubMed          Journal:  Z Krebsforsch        ISSN: 0301-1585


× No keyword cloud information.
  7 in total

1.  The clinical use of fluorescein in neurosurgery; the localization of brain tumors.

Authors:  G E MOORE; W T PEYTON
Journal:  J Neurosurg       Date:  1948-07       Impact factor: 5.115

2.  The clinical use of sodium fluorescein and radioactive diiodofluorescein in the localization of tumors of the central nervous system.

Authors:  G E MOORE; W T PEYTON
Journal:  Minn Med       Date:  1948-10

3.  [Tumor diagnosis with radioactive isotopes. Application and limitations].

Authors:  H CRAMER; H W PABST
Journal:  Munch Med Wochenschr       Date:  1951-07-27

4.  [What the GP should know about isotopes].

Authors:  H CRAMER; H W PABST
Journal:  Med Klin       Date:  1952-01-04

5.  Some preliminary clinical observations on the use of radioactive isotopes for the localization of brain tumours.

Authors:  J G DE WINTER
Journal:  Br J Radiol       Date:  1951-05       Impact factor: 3.039

6.  The localization of cerebral tumours with radioactive derivatives of fluorescein; physical limitations.

Authors:  E H BELCHER; H D EVANS
Journal:  Br J Radiol       Date:  1951-05       Impact factor: 3.039

7.  [Diagnosis of tumors by selective concentration of radioactive phosphorus, fluorides and atabrine].

Authors:  VON H CRAMER; C BRILMAYER; H W PABST
Journal:  Schweiz Med Wochenschr       Date:  1952-01-26
  7 in total
  2 in total

1.  [Diagnosis of carcinoma in gynecology with P32].

Authors:  H CRAMER; H PUDER; G WOLF
Journal:  Arch Gynakol       Date:  1955

2.  Selective uptake of 32P by the cervix in patients with carcinoma before and after treatment, and in normal subjects.

Authors:  A C PAPALOUCAS
Journal:  Br J Cancer       Date:  1958-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.